Mostrar el registro sencillo

dc.contributor.authorRiancho Zarrabeitia, Leyrees_ES
dc.contributor.authorCubería, Maitees_ES
dc.contributor.authorMuñoz, Pedroes_ES
dc.contributor.authorLópez Hoyos, Marcos es_ES
dc.contributor.authorGarcía Canale, Silviaes_ES
dc.contributor.authorGarcía Unzueta, María Teresa es_ES
dc.contributor.authorHernández Hernández, José Luis es_ES
dc.contributor.authorMartínez Taboada, Víctor Manuel es_ES
dc.contributor.otherUniversidad de Cantabriaes_ES
dc.date.accessioned2018-02-06T19:18:43Z
dc.date.available2018-10-01T02:45:10Z
dc.date.issued2017-10es_ES
dc.identifier.issn0049-0172es_ES
dc.identifier.issn1532-866Xes_ES
dc.identifier.urihttp://hdl.handle.net/10902/13004
dc.description.abstractOBJECTIVES: (a) To determine serum 25-OH vitamin D (vitD) levels in primary antiphospholipid syndrome (APS) and to compare them with patients with positive antiphospholipid serology who do not meet clinical criteria for APS, and with healthy controls. (b) To analyze the association of vitD levels with both the clinical manifestations and the immunological profile of patients with primary APS. (c) To perform a meta-analysis evaluating potential differences in serum vitD levels between APS and controls as well as the frequency of vitD deficiency in APS patients. METHODS: Retrospective study including 74 patients with primary APS, 54 with positive antiphospholipid (aPL) serology not meeting clinical criteria for APS, and 215 healthy controls. We considered 30 and 10ng/ml as the thresholds for vitD insufficiency and deficiency, respectively. Meta-analysis included four case-control studies (325 primary APS patients and 507 controls) and was conducted by fitting random effects models and checked for heterogeneity. RESULTS: Median serum vitD levels were similar in the three groups: 21ng/ml in primary APS, 25ng/ml in the aPL-positive group, and 21ng/ml in controls (p = 0.115). However, we found differences in the PTH levels, being 40.4 ± 24.9pg/ml in APS, 34.1 ± 18.2pg/ml in aPL serology, and 23.4 ±12.6pg/ml in healthy controls (p < 0.001). Regarding vitD deficiency, we found significant differences across the groups: 16.2% in APS, 11.1% in patients with positive serology, and 3.7% in controls (p = 0.001). There was a trend for the presence of thrombotic events in patients with vitD deficiency (38.9% vs 19.1%, p = 0.071). The meta-analysis confirmed that the combined mean difference in serum vitD levels between APS and controls was -3.605 (p < 0.001) and that APS patients had an increased frequency of vitD deficiency, with an OR = 3.06 (95% CI: 2.12-4.43, p < 0.001). CONCLUSIONS: APS patients show higher frequency of vitD deficiency than the healthy individuals. The meta-analysis study, including three cohorts and ours, suggests that APS patients have significantly lower serum vitD levels and higher frequency of vitD deficiency than controls.es_ES
dc.format.extent6 p.es_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.rights© 2017, Elsevier. Licensed under the Creative Commons Reconocimiento-NoComercial-SinObraDerivadaes_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.sourceSemin Arthritis Rheum. 2017 Oct 12. pii: S0049-0172(17)30631-5es_ES
dc.subject.otherVitamin Des_ES
dc.subject.otherAntiphospholipid syndromees_ES
dc.subject.otherMeta-analysises_ES
dc.titleVitamin D and antiphospholipid syndrome: A retrospective cohort study and meta-analysises_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherVersionhttps://doi.org/10.1016/j.semarthrit.2017.10.007es_ES
dc.rights.accessRightsopenAccesses_ES
dc.identifier.DOI10.1016/j.semarthrit.2017.10.007es_ES
dc.type.versionacceptedVersiones_ES


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo

© 2017, Elsevier. Licensed under the Creative Commons Reconocimiento-NoComercial-SinObraDerivadaExcepto si se señala otra cosa, la licencia del ítem se describe como © 2017, Elsevier. Licensed under the Creative Commons Reconocimiento-NoComercial-SinObraDerivada